10,792 Shares in Cellectis SA (CLLS) Purchased by Two Sigma Investments LP

Two Sigma Investments LP bought a new stake in Cellectis SA (NASDAQ:CLLS) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 10,792 shares of the biotechnology company’s stock, valued at approximately $180,000.

Several other hedge funds also recently bought and sold shares of the company. Financial Gravity Companies Inc. bought a new stake in Cellectis during the fourth quarter worth $71,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Cellectis by 37.6% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,545 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 1,787 shares during the period. KBC Group NV lifted its holdings in Cellectis by 22.9% during the fourth quarter. KBC Group NV now owns 14,266 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 2,661 shares during the period. Northern Trust Corp bought a new stake in Cellectis during the fourth quarter worth $301,000. Finally, JPMorgan Chase & Co. lifted its holdings in Cellectis by 24,158.5% during the third quarter. JPMorgan Chase & Co. now owns 48,517 shares of the biotechnology company’s stock worth $1,370,000 after acquiring an additional 48,317 shares during the period. Institutional investors own 27.61% of the company’s stock.

NASDAQ:CLLS opened at $20.00 on Wednesday. Cellectis SA has a 1 year low of $15.34 and a 1 year high of $31.57.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, March 11th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.14. Cellectis had a negative return on equity of 18.63% and a negative net margin of 362.48%. The business had revenue of $3.08 million during the quarter, compared to the consensus estimate of $7.46 million. Sell-side analysts anticipate that Cellectis SA will post -2.78 EPS for the current fiscal year.

A number of analysts recently commented on the company. BidaskClub upgraded Cellectis from a “sell” rating to a “hold” rating in a report on Friday, April 5th. ValuEngine upgraded Cellectis from a “sell” rating to a “hold” rating in a report on Monday, April 1st. William Blair assumed coverage on Cellectis in a report on Wednesday, March 13th. They set an “outperform” rating on the stock. Barclays reiterated a “buy” rating and set a $50.00 price target on shares of Cellectis in a report on Wednesday, March 13th. Finally, Citigroup dropped their price target on Cellectis from $37.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, March 11th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Cellectis presently has a consensus rating of “Hold” and an average target price of $32.00.

TRADEMARK VIOLATION NOTICE: This piece was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2019/04/17/10792-shares-in-cellectis-sa-clls-purchased-by-two-sigma-investments-lp.html.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Read More: Golden Cross

Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).

Institutional Ownership by Quarter for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.